Skip to main content
Clinical Trials/ISRCTN65360827
ISRCTN65360827
Completed
Phase 3

A randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's syndrome

niversity of Leeds (UK)0 sites110 target enrollmentJuly 9, 2010

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity of Leeds (UK)
Enrollment
110
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 9, 2010
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Leeds (UK)

Eligibility Criteria

Inclusion Criteria

  • Current inclusion criteria as of 20/09/2011:
  • 1\. Aged between 18 and 80 years of age.
  • 2\. A confirmed diagnosis of primary Sjögren?s syndrome by AECG criteria (see Appendix B).
  • 3\. Positive for anti\-Ro auto\-antibodies.
  • 4\. Patients with a diagnosis of primary Sjögren?s syndrome (by AECG criteria) with more than 10 years disease duration must have at least one systemic feature of:
  • 4\.1 Hypergammaglobulinaemia (IgG over 16\)\*, or
  • 4\.2 Low complement C4\*, or
  • 4\.3 Cryoglobulinaemia
  • 4\.4 Active/past history since diagnosis of the following (ascribed to Sjögren?s Syndrome):
  • 4\.5 purpura/cutaneous vasculitis,

Exclusion Criteria

  • Current exclusion criteria as of 20/09/2011:
  • 1\. Diagnosis of secondary Sjögren?s syndrome.
  • 2\. Use of DMARDs, immunosuppressant therapies or antidepressants within 4 weeks prior to the first dose administration (except for glucocorticoids, salicylates, non\-steroidal anti inflammatory drugs (NSAIDs), methotrexate and analgesics which are acceptable).
  • 3\. Pregnancy, lactation or women of child\-bearing potential (WCBP) unwilling to use medically approved contraception whilst receiving treatment and for 12 months after treatment has finished.
  • 4\. Men whose partners are of child\-bearing potential but who are unwilling to use appropriate medically approved contraception whilst receiving treatment and for 12 months after treatment has finished.
  • 5\. Patient has active or prior hepatitis B or C, known HIV positivity or known history of tuberculosis.
  • 6\. Any history of other autoimmune diseases or other form of immunodeficiency or neutropaenia \<1\.5 109/l.
  • 7\. Any AECG exclusion criteria not covered elsewhere (graft versus host disease, primary lymphoma excluding PSS, sarcoidosis).
  • 8\. Any malignancies that would normally preclude the use of rituximab within the past 5 years, including solid tumours, haematological malignancies and carcinoma in situ (except basal cell or squamous cell carcinoma of the skin that has been excised and cured)
  • 9\. Participation in a clinical study involving administration of an investigational drug within the past 4 weeks prior to the first infusion.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
A randomised double blind placebo controlled clinical trial of the efficacy of an Australian naltrexone implant compared to oral naltrexone for the long-term management of heroin-dependent personsHeroin dependenceMental Health - Addiction
ACTRN12606000308594niversity of Western Australia70
Active, not recruiting
Not Applicable
A clinical trial to show whether there is an improvment in symptoms after the administration of rituximab in patients with primary Sjögren’s syndrome.Primary Sjögren’s syndrome (PSS).MedDRA version: 14.1Level: PTClassification code 10040767Term: Sjogren's syndromeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2010-021430-64-GBniversity of Leeds110
Completed
Not Applicable
A clinical trial to evaluate effects of Misoprostol by sublingual route after delivery of neonate in preventing postpatum bleeding in comparison to intramuscular injection of oxytocin.Health Condition 1: null- Healthy women in labor without known risk factors for Postpartum hemorrhage were studied.
CTRI/2009/091/000672Chittaranjan Sevasadan HospitalSPMukherjee RoadKolkata600
Completed
Phase 2
Chinese herbs in the treatment of laparoscopy diagnosed endometriosis: a controlled study.EndometriosisAlternative and Complementary Medicine - Herbal remediesReproductive Health and Childbirth - Other reproductive health and childbirth disorders
ACTRN12608000619347niversity of Western Sydney150
Active, not recruiting
Phase 1
THE PROBIOTICS FOR ANTIBIOTIC ASSOCIATED DIARRHOEA (PAAD) STUDY Stage II : A double blind randomised placebo controlled trial to determine the effect of probiotics on antibiotic associated diarrhoea in care home residents.Antibiotic Associated DiarrhoeaMedDRA version: 14.1 Level: LLT Classification code 10055956 Term: Antibiotic-associated diarrhoea System Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Body processes [G] - Microbiological Phenomena [G06]
EUCTR2011-006269-17-GBCardiff University, Research & Development Commercial Department400